<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37944296</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8171</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of emergency medicine</Title><ISOAbbreviation>Am J Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research.</ArticleTitle><Pagination><StartPage>122</StartPage><EndPage>127</EndPage><MedlinePgn>122-127</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajem.2023.09.051</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-6757(23)00534-X</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Long COVID has afflicted tens of millions globally leaving many previously-healthy persons severely and indefinitely debilitated. The objective here was to report cases of complete, rapid remission of severe forms of long COVID following certain monoclonal antibody (MCA) infusions and review the corresponding pathophysiological implications.</AbstractText><AbstractText Label="DESIGN">Case histories of the first three index events (among others) are presented. Unaware of others with similar remissions, each subject independently completed personal narratives and standardized surveys regarding demographics/occupation, past history, and the presence and respective severity grading of 33 signs/symptoms associated with long COVID, comparing the presence/severity of those symptoms during the pre-COVID, long-COVID, post-vaccination, and post-MCA phases.</AbstractText><AbstractText Label="SETTING">Patient interviews, e-mails and telephone conversations.</AbstractText><AbstractText Label="SUBJECTS">Three previously healthy, middle-aged, highly-functioning persons, two women and one man (ages 60, 43, and 63&#xa0;years respectively) who, post-acute COVID-19 infection, developed chronic, unrelenting fatigue and cognitive impairment along with other severe, disabling symptoms. Each then independently reported incidental and unanticipated complete remissions within days of MCA treatment.</AbstractText><AbstractText Label="INTERVENTIONS">The casirivimab/imdevimab cocktail.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">Irrespective of sex, age, medical history, vaccination status, or illness duration (18, 8 and 5&#xa0;months, respectively), each subject experienced the same complete remission of their persistent disabling disease within a week of MCA infusion. Each rapidly returned to normal health and previous lifestyles/occupations with normalized exercise tolerance, still sustained to date over two years later.</AbstractText><AbstractText Label="CONCLUSIONS">These index cases provide compelling clinical signals that MCA infusions may be capable of treating long COVID in certain cases, including those with severe debilitation. While the complete and sustained remissions observed here may only apply to long COVID resulting from pre-Delta variants and the specific MCA infused, the striking rapid and complete remissions observed in these cases also provide mechanistic implications for treating/managing other post-viral chronic conditions and long COVID from other variants.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scheppke</LastName><ForeName>Kenneth A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Florida Department of Health, 4052 Bald Cypress Way, Tallahassee, FL 32399, USA; Palm Beach County Fire Rescue, 405 Pike Road, West Palm Beach, FL 33411, USA; Broward Sheriff's Office, 2601 West Broward Boulevard, Ft Lauderdale, FL 33312, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pepe</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Palm Beach County Fire Rescue, 405 Pike Road, West Palm Beach, FL 33411, USA; Broward Sheriff's Office, 2601 West Broward Boulevard, Ft Lauderdale, FL 33312, USA; Broward Health Medical Center, 1600 S Andrews Ave, Fort Lauderdale, FL 33316, USA; Department of Management, Policy and Community Health, School of Public Health, University of Texas Health Sciences Center, 1200 Pressler St, Houston, TX 77030, USA; Dallas County EMS/Public Safety Agencies, Suite 500, 500 Elm St, Dallas, TX 75202, USA. Electronic address: Dr.PaulPepe@GMail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jui</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Oregon Health &amp; Sciences University, CDW-EM, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowe</LastName><ForeName>Remle P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>ESO, 11500 Alterra Pkwy #100, Austin, TX 78758, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheppke</LastName><ForeName>Eric K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Edward Via College of Osteopathic Medicine-Auburn, 910 S Donahue Dr, Auburn, AL 36832, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klimas</LastName><ForeName>Nancy G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Institute for Neuro-Immune Medicine, Nova Southeastern University, 7595 SW 33rd Street, Fourth Floor, Ft Lauderdale, FL 33314, USA; Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL 33125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marty</LastName><ForeName>Aileen M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, Florida International University, 885 SW 109th Ave, PG-5, Suite 1313, Miami, FL, 33199, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Emerg Med</MedlineTA><NlmUniqueID>8309942</NlmUniqueID><ISSNLinking>0735-6757</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="Y">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immune response imbalance</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Monoclonal antibody treatment</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 complications</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None of the authors have any related conflict of interest concerning the elements of this report stewarded by the Florida Department of Health.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>10</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>9</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37944296</ArticleId><ArticleId IdType="doi">10.1016/j.ajem.2023.09.051</ArticleId><ArticleId IdType="pii">S0735-6757(23)00534-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>